Strides Pharma Science Limited — Updates, 18-05-2026: Press Release

Strides Pharma reported strong full-year results: EBITDA at ₹925.3 Cr and Operational PAT at ₹518.1 Cr, up 50% YoY. Ex-US markets drove 21% growth, expanding EBITDA margin to 19%. A dividend of ₹5/share was declared, with net debt improving to 1.55x EBITDA.